Northwestern Mutual Wealth Management’s Protagonist Therapeutics PTGX Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.99M	Sell	48,894 -126	-0.3%	-$13.2K	﹤0.01%	789
2026 Q1	$5.17M	Buy	49,020 +126	+0.3%	+$11.2K	﹤0.01%	791
2025 Q4	$4.27M	Sell	48,894 -10,000	-17%	-$818K	﹤0.01%	821
2025 Q3	$3.91M	Sell	58,894 -20,000	-25%	-$1.14M	﹤0.01%	808
2025 Q2	$4.36M	Hold	78,894	–	–	﹤0.01%	715
2025 Q1	$3.82M	Hold	78,894	–	–	﹤0.01%	733
2024 Q4	$3.05M	Hold	78,894	–	–	﹤0.01%	742
2024 Q3	$3.55M	Sell	78,894 -78,894	-50%	-$3.19M	﹤0.01%	698
2024 Q2	$5.47M	Buy	+157,788	New	+$4.62M	0.01%	572
2024 Q1	–	Sell	-100	Closed	-$2.29K	–	3768
2023 Q4	$2.29K	Buy	+100	New	+$1.75K	﹤0.01%	3034
2022 Q1	–	Sell	-16	Closed	-$1K	–	3336
2021 Q4	$1K	Buy	+16	New	+$506	﹤0.01%	3059

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Northwestern Mutual Wealth Management's PTGX Position: Q2 2026 in Review

Northwestern Mutual Wealth Management reduced its Protagonist Therapeutics (PTGX) stake by 0.26% in Q2 2026, selling an estimated $13.2K and leaving 48,894 shares worth $5.99M. The position accounts for ﹤0.01% of the portfolio, ranked #789.

Northwestern Mutual Wealth Management first reported a position in PTGX in Q4 2021 and has held it in 11 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Northwestern Mutual Wealth Management held 48,894 shares of Protagonist Therapeutics worth $5.99M as of Q2 2026.
Northwestern Mutual Wealth Management sold 126 Protagonist Therapeutics shares in Q2 2026, an estimated $13.2K.
Protagonist Therapeutics made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q2 2026, its #789 holding.
Northwestern Mutual Wealth Management first reported a position in Protagonist Therapeutics in Q4 2021 and has held it in 11 quarters since.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.